Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Republic of Korea.
Lung Cancer. 2010 May;68(2):299-304. doi: 10.1016/j.lungcan.2009.06.016. Epub 2009 Jul 30.
As the population of patients with lung cancer increases, the expenditure on lung cancer treatment will become a huge economic burden in many countries. To support public health services for the treatment of lung cancer, the calculation of lung cancer-specific costs is important.
This study included newly diagnosed 76 lung cancer patients who had survived for at least 5 years after the diagnosis in a tertiary care hospital in South Korea. Direct medical costs were calculated from health care claims obtained from Seoul National University Hospital, which included out-of-pocket expenditures. Direct non-medical and indirect costs were calculated from national statistics.
Mean direct medical costs, direct non-medical costs, and indirect costs amounted to $21,321, $6444 and $4943 respectively, based on an exchange rate of Korean Won 1200=US $1. The average cost for treatment of one lung cancer patient for all 5 years was $32,708. This constituted 44.7% of the per capita income during the same 5-year period.
The economic burden of lung cancer treatment is significant in Korea.
随着肺癌患者人数的增加，肺癌治疗的支出将成为许多国家的巨大经济负担。为了支持治疗肺癌的公共卫生服务，计算肺癌特定成本很重要。
本研究纳入了韩国一家三级保健医院中至少在诊断后存活 5 年的 76 名新诊断肺癌患者。直接医疗费用是根据首尔国立大学医院获得的医保索赔计算的，其中包括自付费用。直接非医疗和间接费用是根据国家统计数据计算的。
根据韩元 1200=1 美元的汇率，直接医疗费用、直接非医疗费用和间接费用的平均值分别为 21321 美元、6444 美元和 4943 美元。所有 5 年的每位肺癌患者的平均治疗费用为 32708 美元。这占同期人均收入的 44.7%。
韩国肺癌治疗的经济负担巨大。
